In the next five years, this field of medicine deserves the attention of all pharmaceutical companies

Pharmaceutical Network Market Analysis: The immune system is the body's defense against external pathogens, protecting us from harmful viruses, bacteria, parasites.
autoimmune diseases are caused by abnormally low or excessive immune system activity leading to the body's immune system mistakenly attack the body's condition, the incidence is more stable.
there are about 100 different types of autoimmune diseases, commonly rheumatoid arthritis, rheumatoid spina bifiditis, psoriasis, etc., these incidence rates are between 0.1% and 0.3%.
the world's pharmaceutical industry, autoimmune diseases has been the second leading treatment field after cancer.
, sales of related drugs in China have increased from 9.8 billion yuan in 2015 to 16.2 billion yuan in 2019 as the prevalence of autoimmune diseases increases.
present, China's autoimmune disease drugs are mainly divided into chemical drugs and biological drugs two categories, and then subdivided, but also divided into small molecules targeted drugs and biological agents.
, small molecule-targeted drugs are represented by tofatib, which targets JAK/STAT signal pathfage, and biologics focus on TNF-α inhibitors.
currently, more than 10 drugs to treat autoimmune diseases are on the market in China, including the top 10 drugs for autoimmune diseases worldwide in 2019.
industry believes that against the background of China's expanding autoimmune disease treatment market, it is expected to grow at a compound annual growth rate of 27.2% from 2020 to 2024, reaching 53.2 billion yuan in 2024 and 133 billion yuan in 2030.
, biologics may grow from 1.2 billion yuan in 2014 to 8.78 billion yuan in 2030, accounting for 66.0% of the total market share of autoimmune drugs, with great potential.
, some industry experts speculate that in the next five years, with the expansion of the autoimmune drug market, there will be a number of drugs with greater market potential.
e.g. Sansheng Guojian's recombinant human type II tumor necrotizing sub-conjugation protein- antibody fusion protein, AbbVie's Adamo monoantigen and its biosimilars, Pfizer's Tofataib and its imitation or will become the mainstay of China's autoimmune disease treatment market, while nearly three years of newly listed Novartis's Skuchiyu monomatics, Johnson's Usnu monoantitors and Sanofi's Duli single resistance will also or will gradually occupy the market market.
that these drugs are characterized by good efficacy, current sales are considerable, and very promising for growth.
To Isep (injection with recombinant human type II. type tumor necrosis group antibody fusion protein), for example, it is the first domestic TNF-α inhibitor listed in the field of rheumatology in China, which can be used to treat moderate and severe active rheumatoid arthritis, moderate to severe plaque psoriasis in adults aged 18 and over, active and straight spina bifia, etc.
2015-2019, its market sales have grown from 842 million yuan to 1.144 billion yuan, with a compound annual growth rate of 8.0%.
growth has slowed, industry insiders predict that Isep will still account for more than 50% of the market in the next 3-5 years.
Overall, in the next 5 years, with the improvement of the diagnosis of autoimmune diseases, the number of groups of autoimmune diseases and policy-driven reasons, China's autoimmune disease drug market size will continue to maintain high growth, and related enterprises will also usher in great opportunities for development.